TFA
STML

Transamerica Financial Advisors’s Stemline Therapeutics, Inc. STML Stock Holding History

Transamerica Financial Advisors’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-500
Closed -$9K – 932
2014
Q4 		$9K Hold
500
– – ﹤0.01% 516
2014
Q3 		$7K Hold
500
– – ﹤0.01% 504
2014
Q2 		$8K Buy
+500
New +$7.67K ﹤0.01% 520

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Transamerica Financial Advisors's STML Position: Q1 2015 in Review

Transamerica Financial Advisors sold out of Stemline Therapeutics, Inc. (STML) in Q1 2015, closing a stake of 500 shares — an estimated $9K sold.

Transamerica Financial Advisors first reported a position in STML in Q2 2014 and held it in 3 quarters. The position peaked at $9K in Q4 2014. 69 funds tracked by Wall St. Rank hold STML as of Q1 2015.

  • Transamerica Financial Advisors reported no remaining Stemline Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
  • Transamerica Financial Advisors sold 500 Stemline Therapeutics, Inc. shares in Q1 2015, an estimated $9K.
  • Transamerica Financial Advisors first reported a position in Stemline Therapeutics, Inc. in Q2 2014 and held it in 3 quarters.
  • Transamerica Financial Advisors's Stemline Therapeutics, Inc. position peaked at $9K in Q4 2014.
  • 69 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2015.

Based on Transamerica Financial Advisors's 13F filing for Q1 2015, filed 12 May 2015.